GSK, SK Bioscience to test COVID-19 vaccine against AstraZeneca shot
Britain’s GSK and South Korea’s SK Bioscience said on Tuesday the drugmakers have begun a late-stage trial of their COVID-19 vaccine candidate to assess immune response when compared with AstraZeneca’s approved shot.
The trial will enrol around 4,000 candidates globally and test SK’s COVID-19 vaccine candidate, GBP510, in combination with GSK’s vaccine booster following positive early-stage data this month.
Results from the GSK-SK study are expected in the first half next year, and the vaccine will be supplied worldwide through the World Health Organization-led vaccine sharing program COVAX if approved, the companies said.
Subscribe to our daily newsletter
Subscribe to INQUIRER PLUS to get access to The Philippine Daily Inquirer & other 70+ titles, share up to 5 gadgets, listen to the news, download as early as 4am & share articles on social media. Call 896 6000.